A new method for high speed, sensitive detection of minimal residual disease

Cytometry Part A

Volumn 81 A, Issue 2, 2012, Pages 169-175

  Liu, Xiaohe ^a,d   Hsieh, H Ben ^a   Campana, Dario ^b,c   Bruce, Richard H ^a  

^a PALO ALTO RESEARCH CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d SRI INTERNATIONAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Image cytometry; Minimal residual disease; Rare cell

Indexed keywords

TUMOR MARKER;

ARTICLE; AUTOMATION; FLOW CYTOMETRY; HUMAN; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

AUTOMATION; CELL LINE, TUMOR; FALSE POSITIVE REACTIONS; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; NEOPLASM, RESIDUAL; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856229635     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21124     Document Type: Article

References (38)

1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
2. Hayes DF, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res 2008; 14: 3646-3650.
3. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
4. Stott SL, Hsu C-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci 2010; 107: 18392-18397.
5. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
6. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010; 16: 5011-5018.
7. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh R-F, Pirzkall A, Fine BM, Amler LC, Chen DS, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010; 5: e12517.
8. Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GA, Kitchingman GR. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675-681.
9. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
10. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
11. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui CH, Campana D. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood; 115: 4657-4663.
12. Neale GAM, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, Campana D. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 934-938.
13. Goulden N, Oakhill A, Steward C. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 112: 275-281.
14. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
15. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 100-106.
16. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui C-H, Campana D. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100: 2399-2402.
17. Brisco MJ, Sykes PJ, Hughes E, Dolman G, Neoh SH, Peng LM, Toogood I, Morley AA. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997; 99: 314-319.
18. van Rhee FMD, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NC, Goldman JM. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
19. Martin H, Atta J, Bruecher J, Elsner S, Schardt C, Stadler M, Melchner Hv, Hoelzer D. In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: Implications for autologous BMT. Ann Hematol 1994; 68: 85-87.
20. Pallisgaard N, Clausen N, Schrøder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999; 26: 355-365.
21. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, et al. A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004; 101: 10501-10504.
22. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893-1899.
23. Bajaj S, Welsh JB, Leif RC, Price JH. Ultra-rare-event detection performance of a custom scanning cytometer on a model preparation of fetal nRBCs. Cytometry 2000; 39: 285-294.
24. Lakowicz JR. Principles of Fluorescence Spectroscopy. 2006; New York: Springer Science + Business Media.
25. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000; 243: 59-75.
26. Cossman J, Neckers LM, Leonard WJ, Greene WC. Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen. J Exp Med 1983; 157: 1064-1069.
27. Braun M, Martin P, Ledbetter J, Hansen J. Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens. Blood 1983; 61: 718-725.
28. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 1-19.
29. Ryan DH, Mitchell SJ, Hennessy LA, Bauer KD, Horan PK, Cohen HJ. Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry. J Immunol Methods 1984; 74: 115-128.
30. Veltroni M, De Zen L, Sanzari M, Maglia O, Dworzak M, Ratei R, Biondi A, Basso G, Gaipa G, I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003; 88: 1245-1252.
31. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112: 8-15.
32. Lee RV, Braylan RC, Rimsza LM. CD58 Expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol 2005; 123: 119-124.
33. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 100-106.
34. Basiji DA, Ortyn WE, Liang L, Venkatachalam V, Morrissey P. Cellular image analysis and imaging by flow cytometry. Clin Lab Med 2007; 27: 653-670.
35. McGrath KE, Bushnell TP, Palis J. Multispectral imaging of hematopoietic cells: Where flow meets morphology. J Immunol Methods 2008; 336: 91-97.
36. Darzynkiewicz Z, Bedner E, Li X, Gorczyca W, Melamed MR. Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res 1999; 249: 1-12.
37. Al-Za'abi AM, Geddie WB, Boerner SL. Equivalence of laser scanning cytometric and flow cytometric immunophenotyping of lymphoid lesions in cytologic samples. Am J Clin Pathol 2008; 129: 780-785.
38. Somlo G LS, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011; 128: 155-163.